Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain.

Antiangiogenic strategy is promising for malignant glioma. Histone deacetylase inhibitors (HDACIs) are unique anticancer agents that exhibit antiangiogenic effects. The in vitro and in vivo antiangiogenic effects of HDACIs, valproic acid (VPA), were investigated in malignant glioma in the brain. In vitro, VPA preferentially inhibited endothelial cell proliferation compared to glioma cell proliferation at the optimum concentration in a dose-dependent manner. VPA reduced vascular endothelial growth factor (VEGF) secretion of glioma cells in a dose-dependent manner under both normoxic and hypoxic conditions. VPA was also found to inhibit tube formation in the angiogenesis assay. In vivo, treatment with VPA combined with irinotecan reduced the number of vessels expressing factor VIII in the brain tumor model. VPA inhibits glioma angiogenesis by direct (inhibition of endothelial cell proliferation and tube formation) and indirect (decreased secretion of VEGF by glioma cells) mechanisms. These data suggest a potential role for VPA as an adjuvant therapy for patients with malignant glioma.

[1]  J. Arbiser,et al.  Novel antiangiogenic agents in dermatology. , 2011, Archives of biochemistry and biophysics.

[2]  A. Matsumura,et al.  Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity , 2010, Brain Tumor Pathology.

[3]  A. Matsumura,et al.  Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth , 2010, Journal of Neuro-Oncology.

[4]  L. Ellis,et al.  Targeting tumor angiogenesis with histone deacetylase inhibitors. , 2009, Cancer letters.

[5]  M. Taphoorn,et al.  Efficacy of anti-epileptic drugs in patients with gliomas and seizures , 2009, Journal of Neurology.

[6]  C. Kramm,et al.  Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma , 2008, Journal of Neuro-Oncology.

[7]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[8]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[9]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Hui Zhang,et al.  Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo , 2007, International journal of urology : official journal of the Japanese Urological Association.

[11]  E. Seto,et al.  HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention , 2007, Oncogene.

[12]  R. Fink,et al.  NA+‐ and K+‐channels as molecular targets of the alkaloid ajmaline in skeletal muscle fibres , 2007, British journal of pharmacology.

[13]  T. Moody,et al.  Modulation of angiogenesis by dithiolethione‐modified NSAIDs and valproic acid , 2007, British journal of pharmacology.

[14]  Kyu-Won Kim,et al.  Regulation of the HIF-1α stability by histone deacetylases , 2007 .

[15]  J. Henkin,et al.  Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. , 2007, Cancer research.

[16]  C. Lau,et al.  Valproic Acid Prolongs Survival Time of Severe Combined Immunodeficient Mice Bearing Intracerebellar Orthotopic Medulloblastoma Xenografts , 2006, Clinical Cancer Research.

[17]  N. Sang,et al.  Histone Deacetylase Inhibitors Repress the Transactivation Potential of Hypoxia-inducible Factors Independently of Direct Acetylation of HIF-α* , 2006, Journal of Biological Chemistry.

[18]  Tao Liu,et al.  Histone deacetylase inhibitors: multifunctional anticancer agents. , 2006, Cancer treatment reviews.

[19]  N. Sang,et al.  Histone Deacetylase Inhibitors Induce VHL and Ubiquitin-Independent Proteasomal Degradation of Hypoxia-Inducible Factor 1α , 2006, Molecular and Cellular Biology.

[20]  C. Pérez-Plasencia,et al.  Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines , 2006, Cancer Cell International.

[21]  C. Lau,et al.  Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC , 2005, Molecular Cancer Therapeutics.

[22]  S. Loitsch,et al.  Modulation of angiogenesis-related protein synthesis by valproic acid. , 2004, Biochemical and biophysical research communications.

[23]  R. Busse,et al.  Valproic acid inhibits angiogenesis in vitro and in vivo. , 2004, Molecular pharmacology.

[24]  Philip Hahnfeldt,et al.  Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. , 2003, Cancer research.

[25]  V. Richon,et al.  HDAC inhibitors for the treatment of cancer. , 2003, Current opinion in investigational drugs.

[26]  U. Förstermann,et al.  Inhibitors of Histone Deacetylation Downregulate the Expression of Endothelial Nitric Oxide Synthase and Compromise Endothelial Cell Function in Vasorelaxation and Angiogenesis , 2002, Circulation research.

[27]  Ricky W. Johnstone,et al.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[28]  M. Guenther,et al.  Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen* , 2001, The Journal of Biological Chemistry.

[29]  Eun-Joung Moon,et al.  Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes , 2001, Nature Medicine.

[30]  大井 祥恵.  Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells , 2009 .

[31]  Robert S Kerbel.  Tumor angiogenesis. , 2008, The New England journal of medicine.

[32]  Kyu-Won Kim,et al.  Regulation of the HIF-1alpha stability by histone deacetylases. , 2007, Oncology reports.

[33]  N. Sang,et al.  Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. , 2006, Molecular and cellular biology.

[34]  N. Sang,et al.  Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. , 2006, The Journal of biological chemistry.

[35]  J. Arts,et al.  Histone Deacetylase Inhibitors: From Chromatin Remodelling to Experimental Cancer Therapeutics , 2005 .